Published in Prostate on June 15, 2010
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. PLoS One (2015) 0.82
Cytokine effects on cell viability and death of prostate carcinoma cells. Biomed Res Int (2014) 0.75
Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst (2008) 8.14
IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med (2005) 5.13
IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol (2003) 2.79
Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate (2006) 1.80
Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med (2008) 1.64
Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res (2008) 1.64
Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother (2003) 1.51
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res (1992) 1.43
Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol (1998) 1.28
Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J Biol Chem (1997) 1.28
PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res (2004) 1.15
Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther (2008) 1.05
Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol (2003) 1.04
Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther (2009) 1.04
Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res (1996) 1.02
Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis (2008) 0.99
PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res (2007) 0.97
Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res (1996) 0.96
Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer (2005) 0.95
Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13. Lab Invest (2001) 0.93
N-linked glycosylation of IL-13R alpha2 is essential for optimal IL-13 inhibitory activity. FASEB J (2006) 0.89
Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol (1995) 0.89
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm (2008) 0.87
CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol (1997) 0.84
Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther (2001) 0.82
Expression of recombinant rat interleukin-13 (IL-13) and generation of a neutralizing rat IL-13 antiserum. Biochem Biophys Res Commun (1997) 0.81
Effects of IL-4 and IL-13 on adenosine receptor expression and responsiveness of the human mast cell line 1. Int Immunopharmacol (2008) 0.80
Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res (2008) 0.79
Sequence databases and microarrays as tools for identifying prostate cancer biomarkers. Urology (2001) 0.78
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A (2005) 4.66
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 2.67
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol (2006) 2.56
XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology (2010) 2.55
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc (2007) 2.45
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol (2005) 2.43
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
North American white mitochondrial haplogroups in prostate and renal cancer. J Urol (2006) 2.13
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res (2006) 2.05
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Addition of intrarectal local analgesia to periprostatic nerve block improves pain control for transrectal ultrasonography-guided prostate biopsy: a systematic review and meta-analysis. Int J Urol (2014) 2.01
Supervised normalization of microarrays. Bioinformatics (2010) 2.00
Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics (2008) 1.95
Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol (2007) 1.81
Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate (2006) 1.80
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet (2012) 1.78
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab (2008) 1.78
Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol (2009) 1.75
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res (2008) 1.64
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis (2008) 1.64
The tuberous sclerosis complex and its highly variable manifestations. J Urol (2003) 1.59
Delayed dark adaptation in 11-cis-retinol dehydrogenase-deficient mice: a role of RDH11 in visual processes in vivo. J Biol Chem (2005) 1.58
Radiation modulation of microRNA in prostate cancer cell lines. Prostate (2008) 1.58
beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res (2006) 1.55
Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image. J Urol (2005) 1.54
Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. Eur Urol (2009) 1.54
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Molecular classification of renal tumors by gene expression profiling. J Mol Diagn (2005) 1.52
Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer (2010) 1.51
Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int (2011) 1.48
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol (2006) 1.44
Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res (2010) 1.44
Posterior lumbar vein off the retrohepatic inferior vena cava: a novel anatomical variant with surgical implications. J Urol (2011) 1.43
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Impact of laparoscopic inguinal hernia repair mesh on open radical retropubic prostatectomy. Urology (2010) 1.42
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007) 1.41
Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res (2005) 1.41
Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res (2011) 1.37
Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation (2002) 1.36
Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone. Semin Cancer Biol (2005) 1.35
Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res (2006) 1.34
β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res (2011) 1.33
Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 1.33
Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer (2006) 1.33